Table 1.
Group mean MOR ligand ED50 values and (95% confidence limits; CL) in the warm water tail withdrawal procedure during continuous naltrexone (NTX) or vaccine treatment (n=5–6 rats).
| Treatment Condition | Test MOR Ligand | ||||
|---|---|---|---|---|---|
| Heroin (SC) ED50 (95% CL) | Heroin (IV) ED50 (95% CL) | Fentanyl (SC) ED50 (95% CL) | Fentanyl (IV) ED50 (95% CL) | ||
| Minipump | + Saline | 0.53 (0.40, 0.71) | 0.21 (0.15, 0.3) | -- | -- |
| + 0.0032 mg/kg/h NTX | 1.08 (0.99, 1.18) | -- | |||
| + 0.01 mg/kg/h NTX | 3.51 (2.69, 4.57) | 1.19 (0.81, 1.77) | |||
| + 0.032 mg/kg/h NTX | 8.47 (6.98, 10.28) | -- | |||
| Vaccine | Pre-vaccine baseline | -- | 0.30 (0.26, 0.35) | 0.016 (0.015, 0.017) | |
| Control | Week 1 | 0.42 (0.33, 0.53) | -- | ||
| Control | Week 2 | -- | 0.016 (0.015, 0.017) | ||
| Control | Week 3 | 0.39 (0.33, 0.47) | -- | ||
| Control | Week 4 | -- | 0.015 (0.013, 0.018) | ||
| Control | Week 5 | 0.36 (0.26, 0.50) | -- | ||
| Control | Week 6 | -- | 0.015 (0.014, 0.017) | ||
| Control | + 0.01 mg/kg/h NTX | -- | 1.27 (0.89, 1.81) | -- | -- |
| Pre-vaccine baseline | 0.38 (0.31, 0.47) | 0.18 (0.16, 0.19) | 0.034 (0.028, 0.042) | 0.014 (0.011, 0.017) | |
| Active | Week1 | 0.65 (0.43, 0.97) | 0.22 (0.17, 0.27) | 0.044 (0.037, 0.0526) | -- |
| Active | Week 2 | -- | -- | -- | 0.016 (0.014, 0.017) |
| Active | Week 3 | 1.37 (1.12, 1.69) | 0.55 (0.52, 0.57) | 0.045 (0.036, 0.056) | -- |
| Active | Week 4 | -- | -- | -- | 0.016 (0.015, 0.018) |
| Active | Week 5 | 1.72 (1.35, 2.19) | 0.39 (0.32, 0.47) | 0.045 (0.038, 0.053) | -- |
| Active | Week 6 | 1.82 (1.42, 2.32) | -- | 0.037 (0.032, 0.043) | 0.017 (0.016, 0.017) |
| Active | Week 7 | -- | 0.62 (0.49, 0.78) | -- | -- |
| Active | Week 8 | 1.58 (1.43, 1.75) | -- | 0.037 (0.026, 0.054) | 0.016 (0.016, 0.017) |
| Active | + 0.01 mg/kg/h NTX | 5.01 (3.93, 6.40) | 1.43 (1.07, 1.9) | 0.10 (0.08, 0.13) | 0.023 (0.015, 0.035) |
--: not tested